DEK Vaccines Limited is a Ghanaian biotechnology and vaccine manufacturing company headquartered in Accra, Ghana, and established as a private sector‑led consortium of leading Ghanaian pharmaceutical firms — Danadams Pharmaceuticals, Ernest Chemists, and Kinapharma. It was formed to deliver on Ghana’s national vision of local vaccine production and improve health security for Ghana and the wider African region.

The company is building one of the largest vaccine manufacturing facilities in Africa, with an estimated investment of over USD 122 million to construct a fill‑and‑finish vaccine plant capable of producing around 600 million doses per year under Good Manufacturing Practice (GMP) conditions. This facility will start with fill and finish production — the stage that prepares bulk vaccine into final dose format — and will expand in phases toward broader vaccine manufacturing, including partnerships for manufacturing Oral Cholera vaccine, pneumococcal conjugate vaccine (PCV‑13), malaria vaccine, HPV, hexavalent, typhoid, rotavirus and more in the coming years.

DEK Vaccines Ltd has attracted strategic support from international partners such as the European Union, which provided development grants, and technology collaborations with organisations including IVI Korea and EuBiologics, as well as agreements for technology transfer for vaccine production and supply. The facility’s development was marked by a ground‑breaking ceremony attended by Ghana’s President, reflecting government and multilateral backing for vaccine sovereignty and production capacity in West Africa.